



LZI Cannabinoids (cTHC) 25 Controls

IVD For In Vitro Diagnostic Use Only



Lin-Zhi International, Inc.

REF	Description	Quantity
0006c 	Cannabinoids (cTHC) 18.75 ng/mL Control	1 x 5 mL
0074c 	Cannabinoids (cTHC) 31.25 ng/mL Control	1 x 5 mL

Intended Use

The Lin -Zhi International, Inc. (LZI) Cannabinoids (cTHC) Controls are for use as assayed quality control materials to monitor the precision of the LZI Cannabinoids (cTHC) Enzyme Immunoassay (Ref# 0070c/0071c) on a number of automated clinical chemistry analyzers.

Description of the Controls:

The LZI Cannabinoids (cTHC) Controls are human urine-based liquids, and ready to use. The constituent is a processed drug-free human urine matrix, containing buffers, stabilizers, and 0.09 % of sodium azide. The controls are prepared by spiking known concentrations of 11-nor- Δ^9 -THC-9-COOH into the drug-free matrix. Throughout this insert cTHC is referenced as an abbreviation for 11-nor- Δ^9 -THC-9-COOH. Controls are made from NIST traceable standards.

*Actual concentrations of these calibrators are within ± 10 % of the target value as determined by GC/MS or LC/MS. Values are provided only as guidelines and laboratories should determine the ranges based on their own test system and tolerance (2).

Precautions and Warning

- *The LZI Cannabinoids (cTHC) Controls are for in vitro diagnostic use only. Harmful if swallowed.*
- *The controls contain sodium azide, which may react with lead or copper plumbing to form potentially explosive metal azide. When disposing such liquids always flush with a large volume of water to prevent azide build-up.*
- *The controls are prepared from non-sterile human urine. They are not tested by licensed reagents for the presence of antibodies to human immunodeficiency viruses, the hepatitis antigens, and/or anti- hepatitis antibodies. They should be handled as potentially infectious. Always apply good laboratory practice to avoid any skin contact or ingestion.*
- *Do not use the controls beyond their expiration dates.*

Preparation and Storage

The controls are provided ready-to-use. No reconstitution is required. Label the cap before removal to identify it with the original bottle. Real-time open- and closed-vial stability studies when stored refrigerated, indicate that expiration dates are at least 18 months from production date. The controls should be stored refrigerated at 2-8°C when not in use.

Stability

When stored refrigerated at 2-8°C, the controls are stable either opened-recapped or unopened until the expiration date printed on the vial label. Real-time open-recapped vial stability studies when stored refrigerated, indicate that expiration dates are at least 18 months from production date. Real-time closed vial stability studies are currently at 60 days of storage and continue to be monitored. Accelerated studies for closed vial stability indicate that expiration dates should be at least 18 months from production date. Store controls tightly capped when not in use. Controls solution dispensed in the sample cups and left on board the clinical analyzer should be discarded after use.

Procedure and Results

Both levels of controls (18.75 ng/mL and 31.25 ng/mL for the 25 ng/mL cutoff) should be run daily to ensure proper assay performance. Additionally, run the controls with each new calibration and after specific maintenance or troubleshooting procedures are performed. For interpretation of results, refer to the appropriate LZI Cannabinoids (cTHC) Enzyme Immunoassay (Ref# 0070c/0071c) package insert (3).

Limitations

The LZI Cannabinoids (cTHC) Controls are for use with the Cannabinoids (cTHC) Enzyme Immunoassay (Ref# 0070c/0071c) to detect cannabinoids in human urine only. Quality control materials should be used in accordance with local, state, and/or federal regulations or accreditation requirements.

Bibliography

1. Urine testing for Drug of Abuse. National Institute on Drug Abuse (NIDA) Research Monograph 73, 1986.
2. Guidance for Industry and FDA Staff, Assayed and Unassayed Quality Control Material. U.S. Department of Health and Human Services. FDA, Document issued on June 7, 2007.
3. LZI Cannabinoids (cTHC) Enzyme Immunoassay (Ref# 0070c/0071c) package insert.

Notice: Adulteration of reagents, use of instruments without appropriate capabilities, or other failure to follow instructions as set forth in this labeling can affect performance characteristics, and stated or implied label claims.



Manufacturer:

Lin-Zhi International, Inc.
2945 Oakmead Village Court
Santa Clara, CA 95051
USA
Tel: (408) 970-8811
Fax: (408) 970-9030
www.lin-zhi.com

EC REP Authorized European Rep. within the EU:

CE REP
CEpartner4U
Esdoornlaan 13
3951 DB Maarn
The Netherlands
www.cepartner4u.eu

